Lynd LD, Traboulsee A, Marra CA, Mittmann N, Evans C, Li KH, Carter M, Hategekimana C.Quantitative analysis of multiple sclerosis patients’ preferences for drug treatment: a best-worst scaling study. Ther Adv Neurol Disord. 2016;9(4):287-96.
OBJECTIVES:The objective of this study was to elicit patients’ preferences for different attributes of MS drug therapy.
METHODS: A representative sample of patients with MS across Canada (n=189) participated in a best-worst scaling study to quantify preferences for different attributes of MS drug therapy, including delaying progression, improving symptoms, preventing relapse, minor side effects, rare but serious adverse events (SAEs), and route of administration.
RESULTS: Analysis revealed heterogeneity of preferences across respondents, with preferences differing across five classes. The most important attributes of drug therapy were the avoidance of SAEs for three classes and the improvement of symptoms for two other classes. Only a smaller group of patients demonstrated a specific preference for avoiding SAEs, and route of administration.
CONCLUSION: This study shows that preferences for drug therapy among patients with MS are different, some of which can be explained by experiences with their disease and treatment. These findings can help to inform the focus of interactions that healthcare practitioners have with patients with MS, as well as further drug development.
What this study says is depending on the drug will influence why you choose it. It appears that one selects the more effective drugs based on their efficacy and the less efficacious drugs based on their side effect. Should this define how we develop drugs?
The only way to get the high efficacy with the low side effect profile if MS is an autoimmune system, is to develop antigen-specific therapy. Should you hold your breath for this?